CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
CTS received notification from Sanochemia Pharmazeutika AG of their intent to immediately discontinu...
As previously mentioned in Zika communications distributed on September 21 and October 12, 2018; ord...
On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...